Ascribe Bio’s new collaboration with Corteva points to a larger shift in AgTech: crop biologicals are moving closer to the seed, where the agronomy is tougher, the economics are harsher, and the commercial upside may be much bigger.
When Ascribe Bio and Corteva said this week that they would work together on seed-treatment uses for Phytalix, the announcement could have been mistaken for a narrow product-development update. In reality, it signals something more consequential. For years, biological crop protection has tried to prove it belongs inside mainstream farm programs rather than at the edges of them. Moving from foliar use to seed treatment is one of the clearest ways to test that claim. The partnership is explicitly aimed at evaluating whether Ascribe’s ascaroside-based Phytalix technology can protect germinating seeds and young seedlings from early-season fungal disease, with Ascribe leading core R&D and Corteva contributing formulation, seed-treatment capability, and agronomic testing across major growing regions.
The seed is where agriculture is least sentimental
Seed treatment matters because it is already one of the least theoretical parts of crop protection. In the American Soybean Association and United Soybean Board’s 2024 survey of 491 growers across the top 17 soybean-producing states, 90% of soybean acres were planted with treated seed. Fungicides were used by 72% of surveyed farmers and insecticides by 66%, which tells you something important: for a large share of commercial agriculture, seed treatment is not a niche add-on. It is part of the operating system.
That same survey also helps explain why the seed stage is so commercially powerful. Farmers are not using treated seed because it sounds progressive; they are using it because the first days of a crop’s life are often the most vulnerable. In the survey, 37% of growers said they would expect a 6% to 10% yield loss without access to seed treatments. About 45% thought they might need additional pesticide volumes if seed treatments disappeared. Just 42% said they would be at least somewhat willing to increase pesticide applications as an alternative, while 80% were somewhat to not at all willing to plant later. In other words, once seed treatment is embedded in the system, the fallback options are not especially attractive.
That is exactly why biologicals are being pulled toward the seed. The promise is not just earlier protection. It is more targeted delivery, potentially fewer in-season field passes, and a cleaner fit with how growers already buy and use inputs. Corteva says seed treatments can reduce the need for some later crop-protection applications, which in turn can mean fewer trips across the field, less soil compaction, lower fuel use, and lower greenhouse-gas emissions. The ASA/USB survey makes a similar point from another angle, arguing that early seed-applied protection can reduce the volume and frequency of later pesticide applications while shielding seedlings when they are most exposed.
This is not just another biologicals press release
There is also a market reason this matters now. Grand View Research estimates the global biological seed treatment market was worth about $1.6 billion in 2024 and could reach $3.25 billion by 2030, with North America accounting for 41% of the market last year. Even if one treats any market forecast cautiously, the direction is hard to miss: seed-applied biologicals are still relatively small, but they are growing fast enough to command serious strategic attention.
And the big companies are behaving accordingly. Corteva said in its latest full-year results that crop-protection volume growth was helped by demand for new products and biologicals. Syngenta, meanwhile, said in February 2025 that it had started up its first world-scale agricultural biologicals production facility in the U.S. and highlighted a widening set of biologicals collaborations. BASF, for its part, said in late 2025 that its biological seed treatment Integral Pro had already protected several million hectares of oilseed rape annually in Europe since 2018, and that EU sunflower trials from 2022 to 2024 showed an average yield increase of 3.5 decitonnes per hectare compared with untreated seed. This is what an industry buildout looks like: capacity, partnerships, registration work, and increasingly specific seed-stage claims.
The Ascribe-Corteva deal also did not emerge from nowhere. In October 2025, Ascribe announced a $12 million Series A financing round co-led by Corteva through its Catalyst platform, alongside Acre Venture Partners, with participation from Syngenta Group Ventures and others. That matters because it suggests large strategics are no longer simply “watching” biological crop protection. They are taking positions early, backing molecules and platforms before they become fully mature commercial products.
The science is unusual. The commercial test is ordinary.
Part of what makes Ascribe interesting is that its technology is not classic biological marketing wrapped around vague microbiome language. Phytalix is based on ascarosides, small natural molecules that can prime pathogen-resistance pathways in plants. The underlying science has been building for years. Cornell-backed researchers reported in 2019 that very small concentrations of ascaroside #18 helped protect soybean, rice, wheat, and maize against major pathogens. Earlier Nature Communications research showed that plants perceive ascarosides and that these molecules can modulate plant defenses. Then, in 2023, researchers identified the Arabidopsis receptor NILR1 as the immune receptor that directly binds ascaroside #18 and is required for the resulting immune signaling and resistance response. This is one reason the Ascribe story feels more substantial than a standard “bio-based” pitch: there is a clearer mechanistic case behind it.
The field data are also intriguing, even if they do not settle the seed-treatment question on their own. In rice trials across 17 sites in India, AgTechNavigator reported that Phytalix reduced bacterial leaf blight severity by 83%, lifted yields by an average of 13% across sites, and delivered yield increases of up to 30% in high-pressure locations. Ascribe’s own release described yield gains of up to 2 tons per hectare. Those are strong signals. But they are signals from foliar or field-use work, not proof that a molecule will succeed once it is compressed into the brutal economics of seed treatment, where dose, stability, coating compatibility, shelf life, and germination safety suddenly matter as much as biological efficacy.
The seed coat is a proving ground
This is the part AgTech sometimes underestimates. Getting onto the seed is not merely a change in application method. It is a change in standard. Corteva’s own seed-treatment process says formulations are evaluated across plantability, application, seed safety, stewardship, efficacy, and regulatory factors. Its seed-applied technology centers screen large numbers of possible combinations and only advance those that perform in both lab and field settings. That is a revealing filter. Biologicals often benefit from broad narratives around sustainability, resilience, or reduced residues. Seed treatment strips away some of that romance. A product either flows through the system, preserves germination, survives the logistics chain, fits the equipment, and delivers field performance — or it does not.
There is a broader regulatory and innovation backdrop here too. In October 2025, the U.S. EPA said it had registered 15 new biopesticide active ingredients since the start of that year. That does not mean all of them will become large commercial products. It does mean the pipeline is thickening, and that the next stage of competition will increasingly be about where these products fit in real farm workflows. The seed is one of the most valuable answers to that question, because it sits at the intersection of agronomy, logistics, labor efficiency, and ROI.
The deeper point is that seed-applied biologicals are attractive not because they are more fashionable than chemistry, but because they may be more integrable than foliar biologicals. Farmers already understand the logic of protecting emergence. They already pay for early-season protection. They already know that replant decisions, weak stands, and extra passes get expensive quickly. Around a fifth of soybean production expenses in 2024 were tied up in seed and pesticide investments, according to the ASA/USB survey, which is exactly why any product entering that part of the budget will be judged ruthlessly. That judgment may be uncomfortable for many biological companies. It is also what could finally make the category credible.
If biologicals can earn a place on the seed, they stop looking like premium add-ons and start looking like infrastructure. That is why the Ascribe-Corteva collaboration matters beyond the companies involved. It suggests the next real contest in crop biologicals will not be fought in marketing decks about sustainability. It will be fought on the seed coat, where agriculture is practical, skeptical, and deeply unforgiving. And that may be exactly the proving ground the sector needs.
